Friday, July 16, 2010

Hypertension- Translating guidelines into Clinical Practice- Dr Chow Yok Wai


Topic : Hypertension- Translating guidelines into Clinical Practice


Speaker: Dr Chow Yok Wai, Consultant Nephrologist and Physician,
Hospital Pantai Ayer Keroh, Melaka

Date: 16/7/2010 7.00pm

Venue: Ramada Renaissance Melaka

Who should attend?
General Practitioners/Primary care physicians
Physicians/Registrar/Medical Officers

Sunday, June 6, 2010

Public Forum- Yong Peng by Dr Chow Yok Wai and Dr Pang Kim Keng

Date : 26/6/2010 (Saturday)

Venue : Yong Peng High School

(Jalan Sekolah Cina, 83700 Yong Peng, Johor)

Time : 6.30pm - 10.00pm

Target of Pax : 150 pax

Speakers: Dr Pang Kim Keng, Consultant Urologist, Hospital Pantai Ayer Keroh, Melaka

Dr Chow Yok Wai, Consultant Nephrologist, Hospital Pantai Ayer Keroh, Melaka



Programme : 6.30pm - Registration

7.00pm - Talk by Dr Pang and Q&A (Common Urological Diseases)

8.00pm - Talk by Dr Chow and Q&A (Protect you kidneys, Control diabetes)

9.00pm - Blood Pressure and Blood Glucose Screening

Wednesday, February 3, 2010

Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephriti

Original Article

Kidney International (2010) 77, 152–160; doi:10.1038/ki.2009.412; published online 4 November 2009
Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis

Jai Radhakrishnan1,6, Dimitrios-Anestis Moutzouris2,6, Ellen M Ginzler3, Neil Solomons4, Ilias I Siempos5 and Gerald B Appel1

Class V lupus nephritis (LN) occurs in one-fifth of biopsy-proven cases of systemic lupus erythematosus. To study the effectiveness of treatments in this group of patients, we pooled analysis of two large randomized controlled multicenter trials of patients with diverse ethnic and racial background who had pure class V disease. These patients received mycophenolate mofetil (MMF) or intravenous cyclophosphamide (IVC) as induction therapy for 24 weeks, with percentage change in proteinuria and serum creatinine as end points. Weighted mean differences, pooled odds ratios, and confidence intervals were calculated by using a random-effects model. A total of 84 patients with class V disease were divided into equal groups, each group had comparable entry variables but one received MMF and one received IVC. Within these groups, 33 patients on MMF and 32 patients on IVC completed 24 weeks of treatment. There were no differences between the groups in mean values for the measured end points. Similarly, no difference was found regarding the number of patients who did not complete the study or who died. In patients with nephrotic syndrome, no difference was noted between those treated with MMF and IVC regarding partial remission or change in urine protein. Hence we found that the response to MMF as induction treatment of patients with class V LN appears to be no different from that to IVC.